Overweight and Obese Adults: Diagnosis and Management

Effective Date: April 1, 2011

Recommendations and Topics



This guideline is intended to provide primary care providers with definitions for overweight and obese classifications in non-pregnant adults aged 19 and older. The guideline contains information on the diagnosis and management of obesity.

Diagnostic Code: 278 Overweight, obesity and other hyperalimentation



The prevalence of overweight and obese adults is increasing dramatically and is associated with chronic diseases such as type 2 diabetes, cardiovascular disease (CVD), hypertension, osteoarthritis, gallbladder disease, and some cancers. In Canada, 36% of adults are overweight, and 23% are in one of the obese categories.1



Calculate patient's body mass index (BMI) and classify patient according to the World Health Organization's (WHO) classification system below:2

Table 1: WHO Categories of BMI

Weight Classification BMI (kg/m2)
Underweight < 18.5
Normal 18.5 - 24.9
Overweight 25 - 29.9
Obese: Class 1 30 - 34.9
Obese: Class 2 35 - 39.9
Obese: Class 3 ≥ 40

Note that BMI does not provide information about the composition or distribution of weight, and cannot distinguish between muscle, bone and fat.3,4 These limitations can cause problems such as:

  • Overestimation of body fat in patients who gain muscle and lose fat, but do not change weight;
  • Underestimation of body fat in older patients because lean body mass gradually declines with age; and
  • Underestimation of body fat in South Asians. Criteria for South Asian populations are:5
    • normal BMI = 18.0-22.9; overweight = 23.0-24.9; obese = ≥ 25.0;

Measure waist circumference, particularly if BMI is ≤ 35, as a progress measuring tool to track body shape change.6,7


  • For patients in overweight or obesity class 1, lifestyle management is recommended.
  • For patients in obesity class 2 or 3, more extensive intervention is required in addition to lifestyle management. All pharmacologic and surgical management strategies in this document pertain only to patients in obesity class 2 or 3.

A higher level of intervention is recommended for patients of all weight classes with co-morbidities that are expected to improve with weight loss (e.g., type 2 diabetes, hypertension, CVD, osteoarthritis, dyslipidemia, sleep apnea). Screening for these conditions is recommended. Follow abnormal findings in accordance with the relevant BC Guideline. Routine chemical urinalysis is not indicated.

In addition, consider screening for eating disorders, depression, and other psychiatric disorders.7

a) Lifestyle Management (Overweight & Obese Class 1-3)

Advise patients on strategies for achieving and maintaining a healthy weight using diet and exercise. This advice is appropriate for patients in the overweight class, or any obesity class.

Refer the patient to a weight loss program, if the program meets the following criteria:

  • Based on a balanced healthy diet (e.g., 500-1000 kcal/day deficit);
  • Encourages regular physical activity;
  • Expects people to lose no more than 0.5-1 kg (1-2 lb) a week; and
  • Establishes an initial weight loss goal of 5-10% of the original weight.6,7

Diets that are restrictive in particular food groups (e.g., protein, fat, carbohydrate) offer no long-term benefit and may be harmful by imposing risk of micronutrient deficiencies. Evidence shows that the benefit of various weight loss regimes is due to calorie restriction.6

The optimal follow-up interval for management of overweight and obese adults is unknown. Most obesity studies followed patients monthly and decreased contact over time (e.g., every 2 weeks, lengthening to every 2 months).6

b) Pharmacologic Management (Obese Class 2, 3)

Pharmaceutical therapy for obesity is recommended only after dietary, exercise, and behavioural approaches have failed. Drug therapy alone is insufficient and should only be used as an adjunct to other weight loss management strategies.

Currently orlistat (Xenical®) is the only medication marketed for the long term treatment of obesity available in Canada. Although long term cardiovascular risk reduction and safety trials continue, no effect on mortality from obesity related conditions has been shown with orlistat.8,9 Choice to pursue pharmaceutical therapy should be made after discussing benefits and limitations with the patient, including: 6,7,9

  • Adverse effects (orlistat side effects may include: oily spotting, steatorrhea, abdominal bloating, fecal incontinence);
  • Monitoring requirements;
  • Lack of long-term efficacy and safety data;
  • Temporary nature of the weight loss achieved;
  • Modest degree of weight loss attributable to the drugs (< 5 kg at 1 year); and
  • Potential impact on the patient's motivation.

Please refer to Appendix A - Prescription Medication Table for Treatment of Obesity in Adults (PDF, 185KB) for more specific medication details.

c) Surgical Intervention (Obese Class 2, 3)

Gastric bypass and laparoscopic band surgery are the most common forms of bariatric surgery procedures. It should be noted that as of publication there is limited availability for these procedures.

Surgery may be considered if: 6,7

  • Patient's BMI is ≥ 40, or ≥ 35 with a related condition (e.g., hypertension, type 2 diabetes, hyperlipidemia, or CVD);
  • All appropriate non-surgical measures have been tried for at least six months without adequate success.

Details of surgical intervention fall outside the scope of this guideline. It is recommended that potential candidates who meet the above criteria are referred to a specialist in bariatric surgery.


Statistics Canada examined the correlation between measured overweight/obesity and three major health risks. This information is presented in Table 2:10

Table 2: Relationship Between Weight Categories and Selected Co-morbidities

  Normal Overweight Obese: Class 1 Obese: Class 2 Obese: Class 3
CVD 3% 5% 7% 7% 7%
Diabetes 2% 4% 10% 12% 12%
Hypertension 9% 15% 20% 30% 30%

Mortality rates for the overweight and obese when compared to mortality rates for those of normal weight, showed significantly increased risk of death in obesity classes II & III (BMI ≥ 35), and the underweight class (BMI < 18.5).11


  1. Tjepkema M. Measured obesity: Adult obesity in Canada. 2004. Available from: http://www.cdha.nshealth.ca/default.aspx?page=DocumentRender&doc.Id=231
  2. World Health Organization. Obesity and overweight. Geneva: World Health Organization; 2003. Available from:
    http://www.who.int/dietphysicalactivity/media/en/gsfs_obesity.pdf (PDF, 210KB)
  3. Green DJ. Is body mass index really the best measure of obesity in individuals? J Am Coll Cardiol. 2009 Feb 10;53(6):526.
  4. Lesser GT. Problems in measurement of body "fatness". J Am Coll Cardiol. 2009 Feb 10;53(6):526-7.
  5. Ramachandran et al. Diabetes in Asia. The Lancet [Internet]. 2009; 375(9712):408-418, ISSN 0140-6736, DOI: 10.1016/S0140-6736(09)60937-5.
  6. National Institute for Health and Clinical Excellence (NICE). Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children. London: National Institute for Health and Clinical Excellence; 2006. Available from:http://www.nice.org.uk/nicemedia/pdf/CG43NICEGuideline.pdf
  7. Lau DCW, Douketis JD, Morrison KM, et al., for the Obesity Canada Clinical Practice Guidelines Expert Panel 2006. Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. CMAJ 2007;176(8 Suppl): online 1-117. Available from: http://www.cmaj.ca/cgi/data/176/8/S1/DC1/1
  8. American College of Physicians (ACP). Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005 Apr 5;142(7):525-31. Available from:http://www.annals.org/cgi/content/full/142/7/525
  9. Rao G. Office Based Strategies for the Management of Obesity. Am Fam Physician 2010 Jun 15;81(12):1449-1455
  10. Statistics Canada, Health Statistics Division. Health Reports 17(3). Ottawa: Statistics Canada; 2006. Available from:http://www.statcan.gc.ca/pub/82-003-x/82-003-x2005003-eng.pdf
  11. Orpana HM, Berthelot JM, Kaplan MS,et al. BMI and Mortality: Results From a National Longitudinal Study of Canadian Adults.Obesity (Silver Spring). 2009 Jun 18.


Appendix A - Prescription Medication Table for the Treatment of Obesity in Adults (PDF, 185KB)

Appendix B - Body Mass Index Chart (Adults) (PDF, 266KB)

The principles of the Guidelines and Protocols Advisory Committee are to:

  • encourage appropriate
    responses to common
    medical situations
  • recommend actions
    that are sufficient
    and efficient, neither
    excessive nor deficient
  • permit exceptions
    when justified by
    clinical circumstances.

Contact Information
Guidelines and Protocols
Advisory Committee
PO Box 9642
Victoria BC V8W 9P1
Web site:



Disclaimer The Clinical Practice Guidelines (the "Guidelines") have been developed by the Guidelines and Protocols Advisory Committee on behalf of the Medical Services Commission. The Guidelines are intended to give an understanding of a clinical problem and outline one or more preferred approaches to the investigation and management of the problem. The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problems.  We cannot respond to patients or patient advocates requesting advice on issues related to medical conditions. If you need medical advice, please contact a health care professional.